Clinical Trials Browser

Phase 2 × efineptakin alfa × 90 days × Clear all

NCT05286060 2026-02-09

GENUINE

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Phase 2 Recruiting

Glioblastoma, Gliosarcoma